Speaker(s): 

Jacob Laser, DO, Resident Physician, Geisinger - has nothing to disclose.

Mentor(s):

Megan Esch, MD, Attending Physician, Geisinger - disclosures with Biogen, TG Therapeutics, Novartis, and Alexion

Learning Objectives:

• familiarize yourself with the current medical therapies available for NMOSD
• assess the efficacy and safety of Inebilizumab as a maintenance therapy for NMOS

At the conclusion of this session, the participant should be able to answer the following questions:

• what are the most common adverse events associated with inevilizumab?
• is there evidence from this study that indicates we should be treating AQP4 seronegative NMO patients differently than seropositive patients?
• What future research studies might be needed to further refine our approach to treating NMO using the currently available agents?

At the conclusion of this session, the participant should be able to answer the following questions:

• what is MIPS surgery?
• how did the ENRICH trial incorporate prior trial data?
• what is the utility weighted MRS and is it a good measure in this patient population?

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Dana Vanino, DO, Cortney Houtz, LPN, Joy Hill, RN, and Sarah Ruhl have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose. 

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPAA compliant. 

Commercial Support for this Session

None